Instalab
logoInstalab

Isovalerylglycine

Urine Test
Help clarify whether an abnormal newborn screen or unexplained metabolic crisis points to an inherited problem with protein breakdown.
4.8 (3,295 reviews)
Tested by Genova Diagnostics
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Self-collect at home
Kit shipped directly to you
Get results
Explained with clear next steps, no medical jargon

Should you take a Isovalerylglycine test?

This test is most useful if any of these apply to you.

Following Up Your Baby's Abnormal Screen
A high C5 newborn screen needs prompt follow-up; urine testing helps distinguish IVA from other causes.
Investigating Unexplained Episodes of Illness
Recurrent vomiting, unusual sleepiness, or unexplained acid buildup may warrant assessment for an inherited metabolic disorder.
Living With a Family History of IVA
Testing can help identify an affected relative without symptoms; carrier testing requires a genetic test.
Managing Diagnosed IVA
Repeat urine results may answer specific questions when interpreted with your treatment, symptoms, and blood results.

About Isovalerylglycine

An abnormal newborn screen, unexplained episodes of serious illness, or a family history can raise the question of an inherited problem with breaking down protein. Urinary isovalerylglycine helps investigate that question. It forms during the breakdown of leucine, an amino acid in dietary protein, and can accumulate when that process is blocked.

This is an established diagnostic marker for isovaleric acidemia. Its interpretation depends on the pattern of other urine compounds, blood results, and sometimes genetic testing. Researchers are also studying it in kidney disease and obesity, but those uses remain exploratory. A routine urine result hasn't been validated as a general measure of metabolic health or longevity.

Where It Comes From

Leucine is broken down in a series of steps inside the energy-producing compartments of your cells. One step depends on the enzyme isovaleryl-CoA dehydrogenase, abbreviated IVD. When this enzyme doesn't work properly, isovaleryl-CoA accumulates and can give rise to isovaleric acid and other compounds.

The liver and kidneys can attach glycine to isovaleryl-CoA. Glycine is an amino acid that your body makes and also gets from food. The resulting isovalerylglycine, or IVG, is considered a nontoxic disposal product and leaves the body in urine. Another route produces isovalerylcarnitine, which contributes to the signal used in newborn blood screening.

Urine IVG is measured with methods that separate compounds and identify them by their molecular mass. This technique is called mass spectrometry. Quantitative results are commonly reported relative to urine creatinine to reduce the effect of dilution. IVG can remain elevated between episodes of illness, making it useful even when someone with the disorder feels well.

Isovaleric Acidemia

Isovaleric acidemia, or IVA, results from disease-causing changes in both copies of the IVD gene, usually inherited one from each parent. Severe cases can cause poor feeding, vomiting, unusual sleepiness, a smell often compared to sweaty feet, acid buildup in the blood, high ammonia, and reduced blood cell counts. Some affected people have a much milder form and remain symptom-free.

Initial urine results can help assess severity, but they don't predict an individual child's course precisely. A German study followed children identified through newborn screening into childhood. Among those with numerical urine IVG results, the initial value tended to be considerably higher in children who later had a metabolic crisis than in those who didn't. The groups overlapped substantially.

The same study found that urine results alone could classify some children with mild disease as having a more severe form. Combining the urine pattern with newborn blood screening results, IVD gene findings, and clinical history gave a more useful assessment.

Early detection and treatment improve the outlook for classic IVA. A meta-analysis of observational studies estimated considerably lower mortality and a much lower rate of developmental delay among people identified through newborn screening than among those diagnosed after symptoms appeared. These pooled estimates describe newborn screening followed by care. They don't measure the benefit of urine testing alone.

The Mild Form Newborn Screening Revealed

Screening whole populations of newborns revealed a mild form of IVA that older clinical reports had largely missed. In a German follow-up study, people classified as having mild IVA had excellent developmental outcomes and no metabolic crises during observation, regardless of maintenance treatment. Elevated IVG therefore doesn't automatically mean that severe illness will develop.

Genetics also has limits as a predictor. In a small South African study, people sharing the same disease-causing IVD variant had presentations ranging from severe illness to no symptoms. The urine pattern, genetic findings, and personal history all contribute to understanding the condition.

Sorting Out an Abnormal Newborn Screen

Newborn blood screening measures a signal called C5 acylcarnitine. Several compounds can contribute to that signal. These include isovalerylcarnitine from IVA, a related compound from a separate disorder of isoleucine breakdown, and pivaloylcarnitine following exposure to certain medicines or skin products.

The urine pattern helps distinguish these possibilities. IVA produces IVG, while the separate condition called 2-methylbutyrylglycinuria produces 2-methylbutyrylglycine. Pivalate exposure can raise the blood screening signal without producing the characteristic urine pattern of IVA. Some screening programs also use additional blood-spot tests to separate these causes.

IVG is most informative as part of that diagnostic pattern. It can also rise in disorders that affect several steps of fat and amino acid breakdown, such as multiple acyl-CoA dehydrogenase deficiency. Those conditions generally produce abnormalities in several urine and blood compounds.

Signals Beyond the Inherited Disorder

Your kidneys remove IVG through both filtration and active transport into urine. Researchers have studied this second process by comparing urine IVG with its concentration in blood. These measurements differ from the amount reported by a urine-only test.

Who Was StudiedWhat Was MeasuredWhat They Found
Black adults in the Jackson Heart Study, with kidney function reassessed years laterIVG clearance calculated from blood and a 24-hour urine collectionLower clearance was associated with higher odds of a substantial later decline in estimated kidney filtration.
170 adults in intensive careThe ratio of IVG in a spot urine sample to IVG in bloodA lower ratio was associated with a higher risk of a combined outcome of worsening kidney function, dialysis dependence, or death within 28 days.
Adults with diabetes, with and without diabetic foot complicationsUrine compounds measured using a research magnetic resonance methodIVG was associated with existing foot complications in an exploratory analysis. This method and study design don't establish how a routine urine IVG result predicts future complications.

The kidney studies required matched blood measurements. A urine IVG concentration alone cannot reproduce their clearance or urine-to-blood calculations. The diabetic foot study compared people who already had complications with people who didn't; it wasn't a test of whether IVG predicts who will develop them.

Glycine Supply and Body Weight

A small study found that adults with severe obesity had lower blood glycine, lower urinary IVG, and slower IVG production than healthy-weight participants. This supports the idea that glycine availability can influence how much IVG is formed. It doesn't establish a low urine result as a diagnosis of glycine deficiency, or a higher result as a health target.

When Results Can Be Misleading

A urine result reflects how much IVG is produced, how it is removed, and how concentrated the sample is. Some changes come from collection conditions; others reflect changes in the body that need clinical context.

  • Urine concentration: creatinine adjustment reduces the effect of dilution, but it doesn't eliminate every source of variation between samples.
  • Illness and fasting: in IVA, infection or inadequate food intake can increase the breakdown of the body's own protein. These are real metabolic changes, and urinary IVG isn't a reliable measure of the immediate severity of a crisis.
  • Treatment: glycine and carnitine change how accumulating compounds are removed. A rising or falling IVG result can therefore have different meanings depending on the treatment being used.
  • Kidney function: IVG disposal depends partly on kidney transport. A low urine concentration alone cannot distinguish low production from altered clearance.
  • Analytical differences: broad organic acid profiles and targeted acylglycine assays can differ in sensitivity, quantification, and reporting units. Similar compounds must be separated correctly, and a qualitative or approximate result cannot be trended as if it were a precise concentration.
  • Newborn screening interference: pivalate exposure affects the blood C5 signal. Discordant blood and urine findings need to be resolved through the full diagnostic workup.

What a Trend Can Show

Serial IVG results can document changes in excretion, but there is no single direction that consistently means better disease control. In established IVA, symptoms, growth, nutritional status, and blood measurements provide the context. During a suspected crisis, blood ammonia, acid-base status, and other urgent assessments guide care; urine IVG is not a substitute.

What Moves This Biomarker

Evidence-backed interventions that affect your Isovalerylglycine level

↑ Increase
Prescribed glycine supplementation in isovaleric acidemia
Glycine can increase the conversion of accumulating isovaleryl-CoA into urinary IVG while reducing free isovaleric acid in blood. Small human studies support this disposal mechanism, and individual cases reported clinical improvement. The size of the urine response varies with dose, leucine intake, and illness.
SupplementStrong Evidence
↓ Decrease
A protein-restricted, leucine-limited diet in classic isovaleric acidemia
Limiting leucine reduces the supply of material entering the blocked pathway and can lower urinary IVG. This is part of standard long-term treatment for classic IVA and helps reduce the burden of accumulating compounds. It does not guarantee that metabolic crises or developmental problems will be prevented.
DietModerate Evidence
↑ Increase
Bariatric surgery in adults with severe obesity
In a small study with paired before-and-after measurements, urinary IVG and its production rate increased several months after bariatric surgery. Blood glycine also increased, consistent with improved glycine availability. The clinical decision to have surgery rests on obesity-related health needs; changing IVG is not an established treatment goal.
ProcedureModerate Evidence
↓ Decrease
Prescription levocarnitine in isovaleric acidemia
Levocarnitine supports removal of accumulating isovaleryl groups as isovalerylcarnitine and treats secondary carnitine deficiency. Because more of the excess leaves as isovalerylcarnitine, urinary IVG can be lower during carnitine treatment alone. In small case studies the IVG response depended on whether glycine was also given, and a lower IVG on carnitine doesn't imply less effective treatment.
MedicationModest Evidence

Frequently Asked Questions

References

41 studies
  1. Eva Thimm, Anselma Riederer, Jerry Vockley, Dries Dobbelaere, Monique Williams, Anita Macdonald, Katharina Dokoupil, Ulrich a. Schatz, Regina E. EnsenauerInternational Journal of Neonatal Screening2025
  2. Du Toit Loots, Elardus Erasmus, Lodewyk Jacobus MienieClinical Chemistry2005
  3. Mary C. Naglak, Rino Salvo, Kevin Madsen, Philip P. Dembure, Louis J. ElsasPediatric Research1988
  4. Toshiyuki Ando, William G. Klingberg, Arthur N. Ward, Karsten Rasmussen, William L. NyhanPediatric Research1971
  5. Hong Chang Tan, Jean W.-C. Hsu, E Shyong Tai, Shaji K. Chacko, Jean‐paul Kovalik, Farook JahoorFrontiers in Endocrinology2024

Isovalerylglycine Testing Options

$405

See the chemical trail your metabolism leaves behind, and explore where your energy, gut, and nutrient pathways may be under strain.

Includes 49 biomarkers:
Isovalerylglycine3-Indoleacetic AcidPhenylacetic AcidDHPPA3-Hydroxyphenylacetic Acid
$509

A comprehensive at-home nutritional and metabolic assessment that analyzes key biomarkers to reveal functional nutrient needs and imbalances.

90 biomarkers
FSA/HSA eligible
No Rx needed
HIPAA compliant